Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Felices

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
JCI Insight|February 9, 2018
Continuous treatment with IL-15 exhausts human NK cells via a metabolic defectMartin Felices, Alexander J Lenvik, Ron McElmurry, et al.
Transplantation and Cellular Therapy|October 3, 2024
N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 TrialAimee Merino, Claudio C Brunstein, Ryan Shanley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 18, 2014
Functional NK cell repertoires are maintained through IL-2Rα and Fas ligandMartin Felices, Todd R Lenvik, Dave E M Ankarlo, et al.
Blood Advances|December 1, 2017
Fewer Circulating Natural Killer Cells 28 Days After Double Cord Blood Transplantation Predicts Inferior Survival and IL-15 ResponseRachel J Bergerson, Robin Williams, Hongbo Wang, et al.
Blood Advances|February 18, 2021
Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantationZachary Davis, Martin Felices, Todd Lenvik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 6, 2018
Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant ImmunotherapyMoniek A de Witte, Dhifaf Sarhan, Zachary Davis, et al.
Gynecologic Oncology|January 20, 2019
Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cellsLocke D Uppendahl, Martin Felices, Laura Bendzick, et al.
Frontiers in Immunology|February 16, 2026
Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicityKate J Dixon, Robert Hullsiek, Sam Wang, et al.
Leukemia|October 24, 2020
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cellsUpasana Sunil Arvindam, Paulien M M van Hauten, Dawn Schirm, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 26, 2021
Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C<sup>+</sup> NK cells to target myeloid leukemiaEmily Chiu, Martin Felices, Frank Cichocki, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
JCI Insight|February 9, 2018
Continuous treatment with IL-15 exhausts human NK cells via a metabolic defectMartin Felices, Alexander J Lenvik, Ron McElmurry, et al.
Transplantation and Cellular Therapy|October 3, 2024
N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 TrialAimee Merino, Claudio C Brunstein, Ryan Shanley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 18, 2014
Functional NK cell repertoires are maintained through IL-2Rα and Fas ligandMartin Felices, Todd R Lenvik, Dave E M Ankarlo, et al.
Blood Advances|December 1, 2017
Fewer Circulating Natural Killer Cells 28 Days After Double Cord Blood Transplantation Predicts Inferior Survival and IL-15 ResponseRachel J Bergerson, Robin Williams, Hongbo Wang, et al.
Blood Advances|February 18, 2021
Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantationZachary Davis, Martin Felices, Todd Lenvik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 6, 2018
Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant ImmunotherapyMoniek A de Witte, Dhifaf Sarhan, Zachary Davis, et al.
Gynecologic Oncology|January 20, 2019
Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cellsLocke D Uppendahl, Martin Felices, Laura Bendzick, et al.
Frontiers in Immunology|February 16, 2026
Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicityKate J Dixon, Robert Hullsiek, Sam Wang, et al.
Leukemia|October 24, 2020
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cellsUpasana Sunil Arvindam, Paulien M M van Hauten, Dawn Schirm, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 26, 2021
Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C<sup>+</sup> NK cells to target myeloid leukemiaEmily Chiu, Martin Felices, Frank Cichocki, et al.
Pageof 8